ArticleEuropean child & adolescent psychiatry2026
Involvement of adiponectin in the biology of attention deficit hyperactivity disorder.
Article in European child & adolescent psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We investigated the involvement of adiponectin in the development of attention-deficit/hyperactivity disorder (ADHD), using a multi-pronged approach integrating cord blood adiponectin concentrations, polygenic risk scores derived from publicly available GWAS summary statistics, and Mendelian randomization. This study aimed to evaluate both upstream genetic influences and downstream adiponectin-level associations. Using a combination of longitudinal cord blood data (N = 531) and genome-wide association studies of ADHD (N = 55,374) and adiponectin (N = 46,434), we examined observational, genetic, and associations linking adiponectin with ADHD. Lower cord blood adiponectin levels were associated with higher ADHD symptoms at ages 5-6 and 8-9, and predicted membership in the increasing-symptom trajectory group. Gene-set analysis demonstrated pathway-level overlap between ADHD and adiponectin regulation. Genetic correlation analysis showed a significant negative correlation between ADHD and adiponectin levels. Mendelian randomization provided stronger evidence for an association of ADHD on adiponectin levels. Polygenic risk score analysis also demonstrated a negative association between genetic liability for ADHD and cord blood adiponectin levels. Additionally, lower adiponectin levels were found to be associated with elevated inflammatory markers in the cord blood samples obtained from the cohort study, which may provide a potential explanation for the higher prevalence of metabolic comorbidities observed in individuals with ADHD. These findings suggest that adiponectin may be associated with the biologyof ADHD and targeting adiponectin regulation may offer a novel approach for managing ADHD and its related health risks.
Indexed as
Identifiers
42446714What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.